findmyKOL
Clinical trialNCT01485835CompletedPhase 1Interventional

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

SponsorEmory UniversityEnrollment8Multiple Myeloma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out what effects, good and/or bad, that ganetespib and bortezomib has on you and your cancer. The investigators will determine the side effects of different dose levels of ganetespib when given alone and the effect it has on your cancer alone. The investigators will also determine the side effects of ganetespib at different dose levels when given in combination with bortezomib and the effect the combination has on your cancer. The study will measure levels of the drug in your blood and bone marrow as well. Bortezomib is a proteasome inhibitor that is approved by the US Food and Drug Administration (FDA) that is used for the treatment of multiple myeloma. The brand name for bortezomib is Velcade®. Ganetespib is considered "investigational" because it has not received approval from the Food and Drug Administration for general use, although it has been previously tested in humans.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Colorado Blood Cancer Institute

    Denver, Colorado, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, United States

  • Emory University Winship Cancer Institute

    Atlanta, Georgia, United States

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, United States

  • Siteman Cancer Center at Washington University

    St Louis, Missouri, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, United States

  • the Center for Cancer and Blood Disorders

    Fort Worth, Texas, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bortezomib →Dexamethasone →Ganetespib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2012
Primary completion
30 Sept 2015
Completion
30 Sept 2015
Last update posted
12 Oct 2015
Registered enrollment
8
Registry id
NCT01485835
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.